A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Overview
This resolution designates September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania. The resolution highlights the prevalence of prostate cancer, its risk factors, and the importance of early detection. It emphasizes the need for men to discuss screening options with their physicians and outlines recommended screening ages based on risk factors. The resolution aims to raise awareness about prostate cancer and encourage preventative measures.
Key provisions
- Designates September 2026 as Prostate Cancer Awareness Month in Pennsylvania.
- Acknowledges the risk of prostate cancer increases with age.
- States that 1 in 8 American men will get prostate cancer.
- Recommends screening starting at age 50 for average risk men.
- Suggests earlier screening (45 or 40 years) for high-risk men.
- Lists symptoms of prostate cancer, including urinary difficulties and pelvic pain.
- Mentions two screening tests: prostate-specific antigen test and digital rectal examination.
- Encourages consultation with a physician regarding screening benefits.
Who is affected
- Men in Pennsylvania
- Families of men with prostate cancer
- Healthcare providers in Pennsylvania
Notable changes
- None explicitly stated in the text.
Bill text
Read the latest version inline or switch to a previous version.
Document of record
- Version
- Pn 3596 Html
- Published
- Not published in the source record
This version is published only as a document. Open the viewer to read it here, or download the file.
Sponsors
Official sponsors from legislative records.
9 on record
Primary sponsor
Cosponsors
Joseph Hohenstein
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours